Vascular Perfusion Solutions Secures $160,000 in Seed Funding for Revolutionary Organ Transplantation Technology

Vascular Perfusion Solutions, Inc. (VPS), a pioneering Medtech company based in Texas, is thrilled to announce that it has successfully raised $160,000 in its latest funding round. This infusion of capital will significantly bolster VPS's mission to transform the organ transplantation landscape through enhanced preservation techniques. At the heart of this endeavor is the VP.S ENCORE®, a state-of-the-art hypothermic machine perfusion device designed for the prolonged preservation of cardiac grafts. By moving past traditional preservation methods like ice-coolers, the VP.S ENCORE® not only simplifies the transplantation process but also makes it accessible at a more affordable price point. Since earning FDA breakthrough device designation in 2021, VPS has conducted successful preclinical tests across more than 100 hearts, such as ovine, porcine, and human specimens, further validating the efficacy and reliability of the VP.S ENCORE®. The recent funding will be strategically allocated towards refining the technology, expanding clinical trials, and accelerating the pathway to market. As VPS continues to innovate within the medical technology space, this funding marks a significant step towards improving organ transplant outcomes and offering hope to countless patients in critical need of life-saving procedures. With a steadfast commitment to improving patient care, VPS aims to set a new standard in cardiac graft preservation and solidify its position as a leading provider in the Medtech industry. Stay tuned for further updates as VPS advances its groundbreaking technology and expands its capabilities in the organ transplantation field.